https://clinicaltrials.gov/ct2/show/NCT03632759
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D
Study Type : Interventional
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: two independent open label, proof of concept studies
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Targeting Beta Cell Dysfunction in Longstanding T1D
Actual Study Start Date : August 15, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : June 2020
